Latest news
Frontier IP: full year outcome “materially ahead of management expectations”
The Group is pleased to provide an update on trading for the year ending 30 June 2021. Following a strong first half, the portfolio continues to make good commercial and technical progress, including an uplift in the value of our holding in Exscientia.
Read moreThe Vaccine Group appoints Jeremy Salt as Chief Executive Officer
Former Chief Scientific Officer of GALVmed and director of Biologicals R&D for Europe, Africa and Middle East of the world’s largest animal health group Zoetis to lead TVG through next phase of development.
Read moreExscientia announces investment of up to $525m led by SoftBank
Our portfolio company Exscientia has completed a Series D funding round led by SoftBank Vision Fund 2 to expand its pipeline and AI-driven drug discovery capabilities.
Read moreOur portfolio
Our portfolio companies are involved in developing a wide range of technologies based on cutting-edge intellectual property to meet the needs and demands of the world.
See all companiesAquaInSilico
AquaInSilico is developing software tools to optimise wastewater treatment across many different industries, including municipal waste water treatment plants, oil groups, brewers, pulp, paper and steel makers, food processing and waste recovery businesses
Learn moreShare price
Share Price InformationLatest downloads
Half Yearly Report 2020
